Business 2 min read By Callum Montgomery
Treace Medical Technologies outlines broader growth beyond its bunion business
Treace Medical Technologies used the Stifel 2026 Healthcare Conference to set out a growth strategy that reaches beyond its core Lapiplasty bunion correction procedure into additional foot and ankle procedures.
Treace Medical Technologies used its presentation at the Stifel 2026 Healthcare Conference to set out a growth strategy that extends beyond its core bunion business. The surgical device company, which focuses on treating foot and ankle conditions, said it is pursuing expansion into additional procedures in the field, a move that would broaden its revenue base beyond the Lapiplasty bunion correction system that anchors its product line.
The company's commercial effort centres on surgeon education and the adoption of its platform. Management told the conference that revenue growth is closely tied to increasing surgeon utilisation and case volume, meaning the number of procedures performed using its products. Expanding the sales force is one of the levers the company is using to support that growth, with the aim of reaching more surgeons and placing its technology in more operating theatres.
Investors are watching two areas closely: the trend in gross margin and the discipline the company shows in controlling operating expenses. Both will be important as Treace seeks to convert a growing surgeon base into sustained profitability while it funds the sales expansion and the development of new procedures. The presentation did not include specific 2026 financial guidance or figures, and the source for this account is a summary of the conference remarks rather than a full financial filing.
The wider market is also crowded. Orthopaedic foot and ankle devices attract a range of established and emerging competitors, and the company's ability to win surgeon loyalty in that environment will shape how far its strategy can take it. The outcome of its planned product launches, and how quickly surgeons adopt them, remains uncertain. Until the company publishes detailed results, investors will have to judge the strategy largely on the direction management has described, rather than on the numbers that would confirm it.
Source: investing.com
4
